Home/Filings/4/A/0001127602-25-008322
4/A//SEC Filing

Smith Stan 4/A

Accession 0001127602-25-008322

CIK 0001878313other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:39 PM ET

Size

8.0 KB

Accession

0001127602-25-008322

Insider Transaction Report

Form 4/AAmended
Period: 2025-02-24
Smith Stan
Director
Transactions
  • Purchase

    Common Stock

    2025-02-24$1.50/sh+50,000$75,0001,180,060 total(indirect: See Footnote)
  • Purchase

    Warrants

    2025-02-24$1.87/sh+50,000$93,50050,000 total(indirect: See Footnote)
    Exercise: $1.87From: 2026-02-24Exp: 2031-02-24Common Stock (50,000 underlying)
Footnotes (5)
  • [F1]The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025.
  • [F2]These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
  • [F3]This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 3 to "February 24, 2025".
  • [F4]These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the inital issuance date.
  • [F5]These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Issuer

MAIA Biotechnology, Inc.

CIK 0001878313

Entity typeother

Related Parties

1
  • filerCIK 0001913199

Filing Metadata

Form type
4/A
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:39 PM ET
Size
8.0 KB